U.S. markets closed

Cellect Biotechnology Ltd. (APOP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.6200+0.0500 (+1.95%)
At close: 4:00PM EDT

Cellect Biotechnology Ltd.

23 Hata’as Street
Kfar Saba 44425
Israel
972 9 974 1444
http://www.cellect.co

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Dr. Shai YarkoniCo-Founder, CEO & DirectorN/AN/A1958
Mr. Eyal LeibovitzChief Financial OfficerN/AN/A1961
Dr. Amos OferChief Operating OfficerN/AN/A1976
Dr. Yael KenanVP of Clinical AffairsN/AN/A1963
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. The company develops ApoTainer, a kit for hematopoietic stem cell transplantation procedures. It has collaborations with the denovoMATRIX group of the Technische Universität Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; Cell2in Inc. to conduct scientific evaluations combining ApoGraft with Cell2in's identification technology FreSHtracer, which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state; and XNK therapeutics to focus on the development of cell-based therapeutics from NK cells. The company was formerly known as Cellect Biomed Ltd. and changed its name to Cellect Biotechnology Ltd. in July 2016. Cellect Biotechnology Ltd. was incorporated in 1986 and is headquartered in Kfar Saba, Israel.

Corporate Governance

Cellect Biotechnology Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.